Down Syndrome (DS) is a genetic disorder caused by the presence of an extra copy of chromosome 21, making a total of 47 chromosomes instead of 46. Some of the common conditions associated with Down Syndrome include intellectual disability, a characteristic facial appearance, and weak muscle tone (hypotonia) in infancy.
People affected with Down Syndrome may have a variety of congenital disabilities, and among these, half of them are born with heart defects. Along with these, other conditions such as digestive abnormalities, leukaemia and hypertension are also common.
Patients with Down Syndrome have an increased risk of dementia with age having a 70% chance of developing dementia after the age of 50
The total diagnosed prevalent population of Down Syndrome in the 7MM was 545,992 in 2017 and estimated to rise at a significant rate during the study period (2017–2030)
Among the European 5 countries, France had the highest diagnosed prevalent population of Down Syndrome, followed by Germany. On the other hand, Spain had the lowest diagnosed prevalent population.
Some of the emerging therapies in Down Syndrome (DS) market includes Pentylenetetrazole (BTD-001), NNI-351, DYRK1A inhibitors, AEF0217, ZSCAN4, and many others.
Some of the key players in the Down Syndrome market include NeuroCircuit Therapeutics, NeuroNascent, KinoPharma, ManRos Therapeutics, Avanti Biosciences, AC immune and others.
For more details visit: https://www.delveinsight.com/report-store/down-syndrome-market
#DownSyndrome #geneticdisorder #genes #disorder #syndrome